You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Dow
AstraZeneca
Moodys
McKinsey
Mallinckrodt
Boehringer Ingelheim

Last Updated: October 21, 2020

DrugPatentWatch Database Preview

Details for Patent: 9,827,231

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Which drugs does patent 9,827,231 protect, and when does it expire?

Patent 9,827,231 protects CLENPIQ and is included in one NDA.

This patent has twelve patent family members in nine countries.

Summary for Patent: 9,827,231
Title:Liquid pharmaceutical composition
Abstract: The present invention provides a physically and chemically stable pharmaceutical liquid composition including sodium picosulfate, magnesium oxide, citric acid and malic acid and methods of making and using such a composition.
Inventor(s): Nam; Bong Gil (Seoul, KR)
Assignee: Ferring International Center S.A. (St. Prex, CH)
Application Number:15/214,768
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 9,827,231
Patent Claim Types:
see list of patent claims
Use; Composition; Formulation;

Drugs Protected by US Patent 9,827,231

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Ferring Pharms Inc CLENPIQ citric acid; magnesium oxide; sodium picosulfate SOLUTION;ORAL 209589-001 Nov 28, 2017 RX Yes Yes   Start Trial   Start Trial Y FOR CLEANSING THE LARGE INTESTINE AS A PREPARATION FOR COLONOSCOPY   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: 9,827,231

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
South Korea10-2014-0032242Mar 19, 2014

International Family Members for US Patent 9,827,231

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Australia 2014386903   Start Trial
Canada 2942878   Start Trial
China 106456534   Start Trial
European Patent Office 3120835   Start Trial
Japan 2017508815   Start Trial
Japan 6347891   Start Trial
South Korea 101420315   Start Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Merck
AstraZeneca
Baxter
McKinsey
McKesson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.